Published in Mol Ther on August 25, 2014
Mesenchymal stem cells for treating ocular surface diseases. BMC Ophthalmol (2015) 0.77
Control of Cross Talk between Angiogenesis and Inflammation by Mesenchymal Stem Cells for the Treatment of Ocular Surface Diseases. Stem Cells Int (2016) 0.75
Ocular Surface Epithelial Thickness Evaluation in Dry Eye Patients: Clinical Correlations. J Ophthalmol (2016) 0.75
The promise of stem cell-based therapeutics in ophthalmology. Neural Regen Res (2017) 0.75
Dry Eye Management: Targeting the Ocular Surface Microenvironment. Int J Mol Sci (2017) 0.75
Data against a Common Assumption: Xenogeneic Mouse Models Can Be Used to Assay Suppression of Immunity by Human MSCs. Mol Ther (2017) 0.75
Lacrimal gland development: from signaling interactions to regenerative medicine. Dev Dyn (2017) 0.75
Mesenchymal stromal cells promote B-cell lymphoma in lacrimal glands by inducing immunosuppressive microenvironment. Oncotarget (2017) 0.75
Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med (2008) 8.79
Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell (2009) 7.62
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood (2004) 6.02
Prevalence of dry eye syndrome among US women. Am J Ophthalmol (2003) 4.46
Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol (2007) 3.96
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 3.11
Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther (2011) 3.06
Utility assessment among patients with dry eye disease. Ophthalmology (2003) 2.71
Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells (2009) 2.71
Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol (2009) 2.65
Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol (2009) 2.60
The epidemiology of dry eye in Melbourne, Australia. Ophthalmology (1998) 2.58
Immunoregulatory function of mesenchymal stem cells. Eur J Immunol (2006) 2.47
Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica (2007) 2.30
Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol (2009) 2.24
Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med (2010) 2.22
Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology (2003) 2.10
Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care (2008) 1.89
Dry eye as a mucosal autoimmune disease. Int Rev Immunol (2013) 1.85
The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci (2005) 1.75
Incidence of dry eye in an older population. Arch Ophthalmol (2004) 1.74
Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol (2008) 1.72
Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology (2008) 1.61
Long-term incidence of dry eye in an older population. Optom Vis Sci (2008) 1.51
Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol (2008) 1.49
Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation (2010) 1.45
Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res (2012) 1.32
Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea (1999) 1.30
T helper cytokines in dry eye disease. Exp Eye Res (2013) 0.97
Animal models of dry eye. Dev Ophthalmol (2008) 0.94
T cell activation by concanavalin A in the presence of cyclosporin A: immunosuppressor withdrawal induces NFATp translocation and interleukin-2 gene transcription. Eur J Immunol (1996) 0.84
Clinicopathological Analysis of Ocular Adnexal Extranodal Marginal Zone B-Cell Lymphoma with IgG4-Positive Cells. PLoS One (2015) 0.89
Dermis-fat graft for treatment of exposed porous polyethylene implants in pediatric postenucleation retinoblastoma patients. Am J Ophthalmol (2011) 0.86
Topical TSG-6 Administration Protects the Ocular Surface in Two Mouse Models of Inflammation-Related Dry Eye. Invest Ophthalmol Vis Sci (2015) 0.79
Clinicopathologic Study of Chromosomal Aberrations in Ocular Adnexal Lymphomas of Korean Patients. Korean J Ophthalmol (2015) 0.78
Clinical characteristics and treatment outcomes of patients with congenital membranous punctal obstruction. J AAPOS (2014) 0.75
Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target. J Cancer Res Clin Oncol (2015) 0.75
Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease. Br J Ophthalmol (2017) 0.75
Blindness in Sweet's Syndrome. Korean J Ophthalmol (2017) 0.75
Early results of surgical management of conjunctival dermolipoma: partial excision and free conjunctival autograft. Br J Ophthalmol (2015) 0.75
Mesenchymal stromal cells promote B-cell lymphoma in lacrimal glands by inducing immunosuppressive microenvironment. Oncotarget (2017) 0.75
Intraoperatively Observed Lacrimal Obstructive Features and Surgical Outcomes in External Dacryocystorhinostomy. Korean J Ophthalmol (2017) 0.75
Association Between Head Tilt and Asymmetric Epiblepharon. JAMA Ophthalmol (2016) 0.75